特利加压素辅助治疗难治性感染性休克:随机安慰剂对照试验
本研究为单中心、前瞻性、双盲、随机安慰剂对照试验,纳入需去甲肾上腺素>0.2 mcg/kg/min或肾上腺素的成人感染性休克患者,1:1随机接受特利加压素或安慰剂。主要终点为随机后6小时平均动脉压≥65 mmHg且总儿茶酚胺等效剂量<0.2 mcg/kg/min的患者比例,特利加压素组显著高于安慰剂组(22.7% vs 9.4%;RR=1.53,95%CI 1.09–2.14;P=0.039)。28天死亡率特利加压素组60.6% vs 安慰剂组64.1%(RR=0.93,95%CI 0.66–1.31;P=0.68),指端缺血发生率28.8% vs 27.4%(P=0.86)。结论认为辅助特利加压素减少了6小时高剂量儿茶酚胺需求比例,但未显著改变死亡率或指端缺血风险。
要点
- 纳入标准:成人感染性休克,需去甲肾上腺素>0.2 mcg/kg/min或肾上腺素。
- 主要终点6小时达标率:特利加压素组22.7% vs 安慰剂组9.4%(RR=1.53,95%CI 1.09–2.14;P=0.039)。
- 28天死亡率:特利加压素组60.6% vs 安慰剂组64.1%(RR=0.93,95%CI 0.66–1.31;P=0.68),无显著差异。
- 指端缺血发生率:特利加压素组28.8% vs 安慰剂组27.4%(P=0.86),无显著差异。
- 基线去甲肾上腺素等效剂量中位数:特利加压素组0.39(0.29–0.73)mcg/kg/min vs 安慰剂组0.39(0.27–0.62)mcg/kg/min。
适用人群与场景
- 成人感染性休克患者,需去甲肾上腺素>0.2 mcg/kg/min或肾上腺素,在内科重症监护病房(ICU)治疗。
诊断标准与关键阈值
- 难治性感染性休克:需去甲肾上腺素>0.2 mcg/kg/min或肾上腺素。
- 主要终点达标:随机后6小时平均动脉压≥65 mmHg且总儿茶酚胺等效剂量<0.2 mcg/kg/min。
研究设计与关键结果
- 单中心、前瞻性、双盲、随机安慰剂对照试验,纳入130例患者(特利加压素组66例,安慰剂组64例)。
- 主要终点6小时达标率:特利加压素组22.7% vs 安慰剂组9.4%(RR=1.53,95%CI 1.09–2.14;P=0.039)。
- 28天死亡率:特利加压素组60.6% vs 安慰剂组64.1%(RR=0.93,95%CI 0.66–1.31;P=0.68)。
- 指端缺血发生率:特利加压素组28.8% vs 安慰剂组27.4%(P=0.86)。
- 基线去甲肾上腺素等效剂量中位数:特利加压素组0.39(0.29–0.73)mcg/kg/min vs 安慰剂组0.39(0.27–0.62)mcg/kg/min。
- 感染来源:特利加压素组肺炎57.6%、腹腔感染21.2%;安慰剂组肺炎48.4%、腹腔感染23.4%。
证据类型、等级与局限
- 证据类型:单中心、前瞻性、双盲、随机安慰剂对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在难治性感染性休克患者中,辅助特利加压素可提高6小时平均动脉压≥65 mmHg且儿茶酚胺等效剂量<0.2 mcg/kg/min的患者比例(22.7% vs 9.4%),但未显著改善28天死亡率(60.6% vs 64.1%)或指端缺血风险(28.8% vs 27.4%)。
指南或共识出处
- 临床试验注册号:Clinicaltrials.gov NCT 04339868,注册日期2020年4月7日。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Terlipressin’s role as an adjunctive vasopressor in septic shock remains controversial. We aimed to evaluate the efficacy of terlipressin versus placebo as an additional vasopressor in refractory septic shock. METHODS: We conducted a single-center, prospective, double-blind, randomized controlled trial in a medical intensive care unit. Adult patients with septic shock requiring norepinephrine > 0.2 mcg/kg/min or epinephrine were randomly assigned (1:1) to receive terlipressin or placebo. The primary outcome was the proportion of patients achieving mean arterial pressure ≥ 65 mmHg with total catecholamine equivalent dose below 0.2 mcg/kg/min at 6 h after randomization. RESULTS: A total of 130 patients were enrolled: 66 in the terlipressin group and 64 in the placebo group. Baseline characteristics were comparable. The median (interquartile range) baseline norepinephrine equivalent dose was 0.39 (0.29 − 0.73) mcg/kg/min for terlipressin versus 0.39 (0.27 − 0.62) mcg/kg/min for placebo. Pneumonia (57.6% vs 48.4%) and intra-abdominal infection (21.2% vs 23.4%) were the most common etiologies in the terlipressin and placebo arms, respectively. Significantly more patients met the primary outcome with terlipressin than with placebo (22.7% vs 9.4%; relative risk [RR] = 1.53, 95% confidence interval [CI] = 1.09–2.14; P = 0.039). The 28-day mortality was 60.6% in the terlipressin group versus 64.1% in the placebo group (RR = 0.93, 95% CI = 0.66–1.31; P = 0.68). Digital ischemia occurred in 28.8% versus 27.4% (P = 0.86). CONCLUSIONS: Among patients with refractory septic shock, adjunctive terlipressin reduced the proportion of patients requiring high-dose catecholamines at 6 h, without significantly altering mortality or digital ischemia risk. TRIAL REGISTRATION: Clinicaltrials.gov (NCT 04339868). The registration date was April 7, 2020.
参考来源
- Tongyoo S, Chayakul C, Aritajati T, et al. Adjunctive terlipressin versus placebo in the treatment of refractory septic shock: a randomized, placebo-controlled trial. Crit Care. 2025. PMID: 41121365. doi:10.1186/s13054-025-05669-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。